CA
NZ
UK
AU
IND
US
…
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Lexicon Pharmaceuticals is a biopharmaceutical company that discovers and develops small-molecule therapies informed by human genetics and commercializes medicines for rare and specialty indications, including an approved treatment for carcinoid syndrome diarrhea. Major long-term growth drivers include scaling sales of its approved therapy, potential label or geographic expansion, and advancement of clinical-stage programs that may generate new revenue streams. The company may appear attractive to investors seeking exposure to a commercial-stage biotech with an active R&D pipeline.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -50.34M | -200.40M | -177.12M | -101.94M | -87.76M |
| Net income | -50.34M | -200.40M | -177.12M | -103.13M | -88.27M |
| Selling general administrative | 37.32M | 143.10M | 97.70M | 48.08M | 32.34M |
| Gross profit | 49.53M | 30.46M | -57.77M | 0.14M | 0.30M |
| Reconciled depreciation | 0.62M | 0.53M | 0.51M | 0.43M | 0.29M |
| Ebit | -42.00M | -184.82M | -170.31M | -100.76M | -87.09M |
| Ebitda | -41.38M | -184.29M | -169.76M | -99.16M | -86.96M |
| Depreciation and amortization | 0.62M | 0.53M | 0.55M | 1.60M | 0.13M |
| Non operating income net other | - | - | - | 1.60M | 0.13M |
| Operating income | -48.91M | -197.12M | -171.75M | -100.76M | -87.09M |
| Other operating expenses | 98.71M | 228.20M | 172.95M | 100.90M | 87.39M |
| Interest expense | 8.34M | 15.58M | 13.10M | 2.78M | 0.80M |
| Tax provision | - | - | - | - | 0.00M |
| Interest income | 6.91M | 12.29M | 6.22M | 1.60M | 0.13M |
| Net interest income | -1.43M | -3.29M | -2.57M | -1.18M | -0.67M |
| Income tax expense | - | -200.40M | 0.39M | 1.18M | 0.51M |
| Total revenue | 49.80M | 31.08M | 1.20M | 0.14M | 0.30M |
| Total operating expenses | 98.44M | 227.58M | 113.98M | 100.90M | 87.39M |
| Cost of revenue | 0.27M | 0.62M | 58.97M | 0.00M | 0.00M |
| Total other income expense net | -1.43M | -3.29M | -5.37M | -1.18M | -0.67M |
| Net income from continuing ops | -50.34M | -200.40M | -157.86M | -101.94M | -87.76M |
| Net income applicable to common shares | - | - | - | -101.94M | -87.76M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 184.99M | 298.42M | 229.43M | 194.30M | 136.91M |
| Other current assets | 3.00M | 4.53M | 5.13M | 2.48M | 2.16M |
| Total liab | 77.45M | 152.47M | 136.32M | 77.17M | 23.31M |
| Total stockholder equity | 107.54M | 145.95M | 93.11M | -1589.72M | -1487.78M |
| Other current liab | 11.55M | 29.27M | 15.87M | 11.49M | 11.88M |
| Common stock | 0.37M | 0.36M | 0.24M | 0.19M | 0.15M |
| Capital stock | 0.37M | 0.36M | 0.24M | 0.19M | 0.15M |
| Retained earnings | -2017.58M | -1967.24M | -1766.84M | -1589.72M | -1487.78M |
| Other liab | - | - | - | - | 23.31M |
| Good will | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M |
| Other assets | - | - | - | - | 136.91M |
| Cash | 34.33M | 66.66M | 22.46M | 46.34M | 64.06M |
| Total current liabilities | 20.87M | 45.25M | 31.55M | 23.17M | 22.12M |
| Net debt | 27.91M | 41.74M | 83.60M | 8.95M | -61.79M |
| Short term debt | 6.24M | 1.18M | 1.29M | 1.29M | 1.09M |
| Short long term debt | 4.59M | - | - | - | - |
| Short long term debt total | 62.24M | 108.40M | 106.06M | 55.29M | 2.28M |
| Other stockholder equity | 2124.72M | 2112.71M | 1859.67M | 0.24M | -0.14M |
| Property plant equipment | - | - | - | 2.07M | 1.18M |
| Total current assets | 101.89M | 246.19M | 176.55M | 140.87M | 88.92M |
| Net tangible assets | - | - | - | 72.58M | 69.05M |
| Short term investments | 61.90M | 171.30M | 147.56M | 92.01M | 22.68M |
| Net receivables | 2.38M | 3.47M | 1.01M | 0.03M | 0.01M |
| Long term debt | 49.41M | 100.30M | 99.51M | 48.58M | - |
| Inventory | 0.28M | 0.23M | 0.38M | - | - |
| Accounts payable | 3.08M | 14.80M | 14.39M | 10.39M | 9.15M |
| Accumulated other comprehensive income | 0.03M | 0.12M | 0.03M | -0.43M | -0.01M |
| Common stock total equity | - | - | - | 0.19M | 0.15M |
| Retained earnings total equity | - | - | - | -1589.72M | -1487.78M |
| Treasury stock | - | - | - | -2.06M | -7.52M |
| Non currrent assets other | 29.37M | 0.37M | 0.83M | 6.82M | 2.27M |
| Non current assets total | 83.09M | 52.23M | 52.88M | 53.43M | 47.99M |
| Capital lease obligations | 8.82M | 8.10M | 6.56M | 6.71M | 2.28M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 113.02M | -15.38M | -77.67M | -69.75M | 3.33M |
| Change to liabilities | - | - | - | 0.08M | -14.16M |
| Total cashflows from investing activities | 113.02M | -15.38M | -49.94M | -71.08M | 2.11M |
| Net borrowings | -48.00M | 0.00M | 49.96M | 48.87M | -11.70M |
| Total cash from financing activities | -48.50M | 238.35M | 187.96M | 142.21M | 22.71M |
| Change to operating activities | - | - | - | 0.34M | 3.55M |
| Net income | -50.34M | -200.40M | -177.12M | -101.94M | -87.76M |
| Change in cash | -3.33M | 44.19M | -23.88M | -17.72M | -62.20M |
| Begin period cash flow | 66.66M | 22.46M | 46.34M | 64.06M | 126.26M |
| End period cash flow | 63.33M | 66.66M | 22.46M | 46.34M | 64.06M |
| Total cash from operating activities | -67.85M | -178.78M | -161.90M | -88.85M | -87.02M |
| Issuance of capital stock | 0.00M | 241.32M | 138.76M | 94.20M | 37.08M |
| Depreciation | 0.62M | 0.53M | 0.55M | 0.43M | 0.29M |
| Other cashflows from investing activities | 3.71M | 9.30M | - | - | - |
| Dividends paid | - | - | 99.92M | - | -11.70M |
| Change to inventory | -0.05M | 0.15M | -0.38M | 0.00M | 0.00M |
| Change to account receivables | 1.09M | -2.46M | -0.98M | -0.01M | 0.38M |
| Sale purchase of stock | -0.57M | -1.73M | -0.82M | -0.86M | -2.67M |
| Other cashflows from financing activities | -0.57M | 240.01M | -49.94M | 97.74M | 11.70M |
| Change to netincome | - | - | - | 11.52M | 10.63M |
| Capital expenditures | 0.00M | 1.03M | 0.47M | 1.33M | 1.22M |
| Change receivables | - | - | - | -0.01M | 0.38M |
| Cash flows other operating | - | - | - | 0.34M | 3.55M |
| Cash and cash equivalents changes | - | - | - | -17.72M | -62.20M |
| Change in working capital | -26.89M | 14.24M | 2.66M | 0.40M | -10.23M |
| Stock based compensation | 12.52M | 13.50M | 14.34M | 11.52M | 10.58M |
| Other non cash items | -3.75M | -6.65M | -2.33M | 0.74M | 0.05M |
| Free cash flow | -67.85M | -179.81M | -162.37M | -90.18M | -88.24M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LXRX Lexicon Pharmaceuticals Inc |
- -% |
1.48 | - | - | 21.57 | 5.05 | 18.08 | 16.57 |
| NVO Novo Nordisk A/S |
1.99 4.95% |
42.18 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.28 3.44% |
549.04 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-41.91 4.31% |
931.45 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381
281 863 3000
81
| Name | Title | Year Born |
|---|---|---|
| Mr. Lonnel Coats | CEO & Director | 1965 |
| Mr. Jeffrey L. Wade J.D. | Pres & CFO | 1965 |
| Mr. Brian T. Crum | Sr. VP, Gen. Counsel & Sec. | 1973 |
| Dr. Alan J. Main Ph.D. | Exec. VP of Innovation & Chemical Sciences | 1954 |
| Dr. Craig B. Granowitz M.D., Ph.D. | Sr. VP & Chief Medical Officer | 1965 |
| Dr. Robert J. Lefkowitz M.D. | Consultant & Independent Director | 1944 |
| Ms. Kristen L. Alexander | VP of Fin. & Accounting | 1968 |
| Mike Kelly | Investor Relations Officer | NA |
| Chas Schultz | Exec. Director of Corp. Communications & Patient Advocacy | NA |
| Ms. Wendy E. McDermott | VP of HR | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+2.10%
Communication Services
+1.48%
Consumer Cyclical
+2.12%
Consumer Defensive
+1.59%
Energy
-2.52%
Financial Services
+1.11%
Financials
-6.05%
Healthcare
+2.12%
Industrials
-0.12%
Real Estate
+1.25%
Technology
-0.07%
Utilities
+0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...